For more than 20 years, we’ve been focused on addressing social determinants of health or as we like to call them, essential needs. We’re thrilled to that we no longer have to convince the healthcare system that factors like food, heat and housing are key to good health and are honored to be working alongside so many amazing organizations who are integrating essential needs interventions into care.

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us

Events

Related News

Business Insights

HALOZYME COMPLETES ANTARES PHARMA ACQUISITION

Halozyme Therapeutics, Inc. | May 30, 2022

news image

Halozyme Therapeutics, Inc. announced the successful completion of its acquisition of Antares Pharma, Inc. The tender offer for all of the outstanding shares of Antares common stock expired as scheduled at one minute after 11:59 p.m., Eastern Time, on Monday, May 23, 2022. The minimum tender condition and all of the other conditions to the offer have been satisfied and on May 24, 2022, Halozyme accepted for payment and will promptly pay for all shares validly tendered and not vali...

Read More

Business Insights

SEAGEN AND SANOFI ANNOUNCED PARTNERSHIP FOR THE DEVELOPMENT AND COMMERCIALIZATION OF MULTIPLE NOVEL ANTIBODY-DRUG CONJUGATES

Seagen Inc. | March 17, 2022

news image

Sanofi and Seagen signed an exclusive partnership agreement to discover, develop, and market antibody-drug conjugates targeting three cancer targets. Sanofi's patented monoclonal antibody technology and Seagen's proprietary ADC technology will be used. Sanofi presently has one ADC under development, an antibody designed to deliver strong anti-cancer medications to tumor cells expressing a particular protein. “We are excited to be working with Sa...

Read More

SALESFORCE LAUNCHES NEW HYBRID CMS PLATFORM 'SALESFORCE CMS’

DECK 7 | February 04, 2020

news image

Demand owns content, and with the release of 'Salesforce CMS', it’s clear that Salesforce is putting the control squarely with demand, not to mention delighting the creative marketer with more power through additional tools for creating content that are expected to work well right out of the box (er… cloud). Customers have become accustomed to consuming content across multiple channels and platforms which requires marketers to provide for seamless integration of their conten...

Read More

Research

GILEAD GETS WHO COLD SHOULDER FOR REMDESIVIR IN COVID-19, LAUNCHES SPEEDY DEFENSE

Gilead | November 21, 2020

news image

Gilead Sciences’ Veklury, better known as remdesivir, is so far the only COVID-19 therapy officially approved by the FDA, but the World Health Organization has some other ideas about the drug’s worth. At clear odds with the FDA’s approval, the WHO has for now recommended against the use of remdesivir in any hospitalized patients—regardless of disease severity—after an expert panel said it had found no evidence that remdesivir has any meaningful effect...

Read More
news image

Business Insights

HALOZYME COMPLETES ANTARES PHARMA ACQUISITION

Halozyme Therapeutics, Inc. | May 30, 2022

Halozyme Therapeutics, Inc. announced the successful completion of its acquisition of Antares Pharma, Inc. The tender offer for all of the outstanding shares of Antares common stock expired as scheduled at one minute after 11:59 p.m., Eastern Time, on Monday, May 23, 2022. The minimum tender condition and all of the other conditions to the offer have been satisfied and on May 24, 2022, Halozyme accepted for payment and will promptly pay for all shares validly tendered and not vali...

Read More
news image

Business Insights

SEAGEN AND SANOFI ANNOUNCED PARTNERSHIP FOR THE DEVELOPMENT AND COMMERCIALIZATION OF MULTIPLE NOVEL ANTIBODY-DRUG CONJUGATES

Seagen Inc. | March 17, 2022

Sanofi and Seagen signed an exclusive partnership agreement to discover, develop, and market antibody-drug conjugates targeting three cancer targets. Sanofi's patented monoclonal antibody technology and Seagen's proprietary ADC technology will be used. Sanofi presently has one ADC under development, an antibody designed to deliver strong anti-cancer medications to tumor cells expressing a particular protein. “We are excited to be working with Sa...

Read More
news image

SALESFORCE LAUNCHES NEW HYBRID CMS PLATFORM 'SALESFORCE CMS’

DECK 7 | February 04, 2020

Demand owns content, and with the release of 'Salesforce CMS', it’s clear that Salesforce is putting the control squarely with demand, not to mention delighting the creative marketer with more power through additional tools for creating content that are expected to work well right out of the box (er… cloud). Customers have become accustomed to consuming content across multiple channels and platforms which requires marketers to provide for seamless integration of their conten...

Read More
news image

Research

GILEAD GETS WHO COLD SHOULDER FOR REMDESIVIR IN COVID-19, LAUNCHES SPEEDY DEFENSE

Gilead | November 21, 2020

Gilead Sciences’ Veklury, better known as remdesivir, is so far the only COVID-19 therapy officially approved by the FDA, but the World Health Organization has some other ideas about the drug’s worth. At clear odds with the FDA’s approval, the WHO has for now recommended against the use of remdesivir in any hospitalized patients—regardless of disease severity—after an expert panel said it had found no evidence that remdesivir has any meaningful effect...

Read More